|Bid||69.50 x 3000|
|Ask||70.10 x 1000|
|Day's range||69.39 - 76.09|
|52-week range||41.17 - 107.79|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||225.42|
|Earnings date||10 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||63.50|
The pandemic gave a boost to a trend that was already growing -- telehealth. Before the pandemic, telehealth was often seen by companies as a convenient option to save money on insurance costs, but during the pandemic, it became a necessity. Going forward, consumers, having seen how easy telehealth services can be for prescription refills, mental wellness, and other areas, are going to expect telehealth options.
Our trio of contributors offer three COVID-19 stocks that will zoom higher, even as we emerge from the pandemic.
Doximity (NYSE: DOCS), an online networking platform for medical professionals, already has 80% of doctors in the U.S. using its platform. In this video from "Beat & Raise" on Motley Fool Live, recorded on Sept. 23, Fool.com contributors Taylor Carmichael and Brian Withers; along with tech, healthcare, and cannabis editor and analyst Olivia Zitkus; discuss Doximity's next opportunity, and why it will be so hard for competitors to beat. Olivia Zitkus: I'm curious, since Doximity has already looped in, 80% of doctors to its platform.